These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 29227683)

  • 1. Discovery of Peptidomimetic Antibody-Drug Conjugate Linkers with Enhanced Protease Specificity.
    Wei B; Gunzner-Toste J; Yao H; Wang T; Wang J; Xu Z; Chen J; Wai J; Nonomiya J; Tsai SP; Chuh J; Kozak KR; Liu Y; Yu SF; Lau J; Li G; Phillips GD; Leipold D; Kamath A; Su D; Xu K; Eigenbrot C; Steinbacher S; Ohri R; Raab H; Staben LR; Zhao G; Flygare JA; Pillow TH; Verma V; Masterson LA; Howard PW; Safina B
    J Med Chem; 2018 Feb; 61(3):989-1000. PubMed ID: 29227683
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cathepsin B Is Dispensable for Cellular Processing of Cathepsin B-Cleavable Antibody-Drug Conjugates.
    Caculitan NG; Dela Cruz Chuh J; Ma Y; Zhang D; Kozak KR; Liu Y; Pillow TH; Sadowsky J; Cheung TK; Phung Q; Haley B; Lee BC; Akita RW; Sliwkowski MX; Polson AG
    Cancer Res; 2017 Dec; 77(24):7027-7037. PubMed ID: 29046337
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel Phosphate Modified Cathepsin B Linkers: Improving Aqueous Solubility and Enhancing Payload Scope of ADCs.
    Kern JC; Dooney D; Zhang R; Liang L; Brandish PE; Cheng M; Feng G; Beck A; Bresson D; Firdos J; Gately D; Knudsen N; Manibusan A; Sun Y; Garbaccio RM
    Bioconjug Chem; 2016 Sep; 27(9):2081-8. PubMed ID: 27469406
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitative Conjugated Payload Measurement Using Enzymatic Release of Antibody-Drug Conjugate with Cleavable Linker.
    Rago B; Tumey LN; Wei C; Barletta F; Clark T; Hansel S; Han X
    Bioconjug Chem; 2017 Feb; 28(2):620-626. PubMed ID: 28140559
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Novel Chemical Linkers for Next-generation Antibody-drug Conjugates(ADCs)].
    Tsuchikama K
    Yakugaku Zasshi; 2019; 139(2):209-219. PubMed ID: 30713230
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimizing Lysosomal Activation of Antibody-Drug Conjugates (ADCs) by Incorporation of Novel Cleavable Dipeptide Linkers.
    Salomon PL; Reid EE; Archer KE; Harris L; Maloney EK; Wilhelm AJ; Miller ML; Chari RVJ; Keating TA; Singh R
    Mol Pharm; 2019 Dec; 16(12):4817-4825. PubMed ID: 31609629
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lysosomal-Cleavable Peptide Linkers in Antibody-Drug Conjugates.
    Balamkundu S; Liu CF
    Biomedicines; 2023 Nov; 11(11):. PubMed ID: 38002080
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cleavable linkers in antibody-drug conjugates.
    Bargh JD; Isidro-Llobet A; Parker JS; Spring DR
    Chem Soc Rev; 2019 Aug; 48(16):4361-4374. PubMed ID: 31294429
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rapid, High-Yielding Solid-Phase Synthesis of Cathepsin-B Cleavable Linkers for Targeted Cancer Therapeutics.
    Pryyma A; Gunasekera S; Lewin J; Perrin DM
    Bioconjug Chem; 2020 Dec; 31(12):2685-2690. PubMed ID: 33274932
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular Basis of Valine-Citrulline-PABC Linker Instability in Site-Specific ADCs and Its Mitigation by Linker Design.
    Dorywalska M; Dushin R; Moine L; Farias SE; Zhou D; Navaratnam T; Lui V; Hasa-Moreno A; Casas MG; Tran TT; Delaria K; Liu SH; Foletti D; O'Donnell CJ; Pons J; Shelton DL; Rajpal A; Strop P
    Mol Cancer Ther; 2016 May; 15(5):958-70. PubMed ID: 26944918
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of attachment site on stability of cleavable antibody drug conjugates.
    Dorywalska M; Strop P; Melton-Witt JA; Hasa-Moreno A; Farias SE; Galindo Casas M; Delaria K; Lui V; Poulsen K; Loo C; Krimm S; Bolton G; Moine L; Dushin R; Tran TT; Liu SH; Rickert M; Foletti D; Shelton DL; Pons J; Rajpal A
    Bioconjug Chem; 2015 Apr; 26(4):650-9. PubMed ID: 25643134
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimization of a pendant-shaped PEGylated linker for antibody-drug conjugates.
    Tedeschini T; Campara B; Grigoletto A; Zanotto I; Cannella L; Gabbia D; Matsuno Y; Suzuki A; Yoshioka H; Armirotti A; De Martin S; Pasut G
    J Control Release; 2024 Nov; 375():74-89. PubMed ID: 39216599
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo drug-linker stability of an anti-CD30 dipeptide-linked auristatin immunoconjugate.
    Sanderson RJ; Hering MA; James SF; Sun MM; Doronina SO; Siadak AW; Senter PD; Wahl AF
    Clin Cancer Res; 2005 Jan; 11(2 Pt 1):843-52. PubMed ID: 15701875
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development and Properties of Valine-Alanine based Antibody-Drug Conjugates with Monomethyl Auristatin E as the Potent Payload.
    Wang Y; Fan S; Zhong W; Zhou X; Li S
    Int J Mol Sci; 2017 Aug; 18(9):. PubMed ID: 28841157
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of cathepsin B-sensitive triggers and hydrophilic linkers on in vitro efficacy of novel site-specific antibody-drug conjugates.
    Bryden F; Martin C; Letast S; Lles E; Viéitez-Villemin I; Rousseau A; Colas C; Brachet-Botineau M; Allard-Vannier E; Larbouret C; Viaud-Massuard MC; Joubert N
    Org Biomol Chem; 2018 Mar; 16(11):1882-1889. PubMed ID: 29473076
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison of the activity, lysosomal stability, and efficacy of legumain-cleavable and cathepsin-cleavable ADC linkers.
    Gray ME; Zielinski KM; Xu F; Elder KK; McKay SJ; Ojo VT; Benjamin SR; Yaseen AA; Brooks TA; Tumey LN
    Xenobiotica; 2024 Aug; 54(8):458-468. PubMed ID: 38738708
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protease-Cleavable Linkers Modulate the Anticancer Activity of Noninternalizing Antibody-Drug Conjugates.
    Dal Corso A; Cazzamalli S; Gébleux R; Mattarella M; Neri D
    Bioconjug Chem; 2017 Jul; 28(7):1826-1833. PubMed ID: 28662334
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel peptide linkers for highly potent antibody-auristatin conjugate.
    Doronina SO; Bovee TD; Meyer DW; Miyamoto JB; Anderson ME; Morris-Tilden CA; Senter PD
    Bioconjug Chem; 2008 Oct; 19(10):1960-3. PubMed ID: 18803412
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cathepsin B Cleavage of vcMMAE-Based Antibody-Drug Conjugate Is Not Drug Location or Monoclonal Antibody Carrier Specific.
    Gikanga B; Adeniji NS; Patapoff TW; Chih HW; Yi L
    Bioconjug Chem; 2016 Apr; 27(4):1040-9. PubMed ID: 26914498
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Engineering Enzyme-Cleavable Oligonucleotides by Automated Solid-Phase Incorporation of Cathepsin B Sensitive Dipeptide Linkers.
    Jin C; Ei-Sagheer AH; Li S; Vallis KA; Tan W; Brown T
    Angew Chem Int Ed Engl; 2022 Mar; 61(13):e202114016. PubMed ID: 34953094
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.